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To the ranch and back – benefits vs. costs
in altered radiotherapy for head and neck cancers*
Bogus∏aw Maciejewski1, Rafa∏ Tarnawski1, Leszek Miszczyk1, Andrzej Hliniak2,
Rafa∏ Suwiƒski1
A i m  o f  s t u d y.  To analyze the benefit and costs of clinical trials on altered fractionated radiotherapy for head and neck can-
cer. Doubts and uncertainties concerning overall therapeutic gain are discussed.
M a t e r i a l  a n d  m e t h o d s. Data sets of 12 clinical trials most often cited in the literature, including all together 4682 ca-
ses of head and neck cancer are included into the analysis. They represent all tumours stages and sites and wide variety of al-
tered fractionation schedules, i.e. accelerated (AF), hyperfractionated (HF) and hybrid accelerated hyperfractionated (AHF)
regimes. At least 3-year locoregional control and the incidence of consequential late effects and true late complications are used
as end-points for benefits and costs respectively.
Re s u l t s.  In some studies AF/AHF regimens were superior for advanced tumours (CHART, EORTC 22791) but not for T2,
whereas in others significant benefit was noted for tumours smaller than 4 cm (PMH). Various uncertainties arise concerning
selection and dosimetric biases. Interpretation of the costs is even more uncertain than that of the LRC benefit. Grade 2 and
3 late effects (LE) are often groupped together, several events may occur in the same patient. Whilst the LRC is quantified as
actuarial, the LE is presented as a crude data. Moreover, consequential late effects can mostly be only deducted from the pu-
blished results. Thus the costs are generally underestimated. For some trials (Cairo, EORTC 22851), LRC benefit and the TG
is apparently positive, but precise quantitation of LE and CLE makes some trials negative. Final analysis suggests that an ove-
rall therapeutic gain is moderate in the range of 0-15%. Analysis of the Normalized Total Doses corrected for changes in frac-
tion size and overall treatment time and recalculated for 50% probability of the LRC (NTCD5o) shows an average of 0.6
Gy/day balancing tumour clonogen repopulation might be to low, and it can increase to 0.85 Gy/day or even 1.1-1.2 Gy/day
during the weekends. Furthermore, it seems that the lag period could be shorten to 14-21 days.
C o n c l u s i o n s.  The results convincingly suggest that the TG may likely be seriously constrained by the intention to use to-
tal doses limited to the level of acute tolerance, which however does not seem to be dose-limiting. Intensive regimen with twi-
ce-a-day fractions, and without or slight reduction in total dose can only be delivered by escalating the dose beyond working
days, that means, including weekends. DAHANCA-7 and CAIR trials support this concept. However, for such intensive tre-
atment the safe window is narrow, and small change in time or dose can shift enhanced but tolerable mucosal morbidity to-
wards very severe and intolerable late complications. Despite two decreases of extensive studies the question what should be
the best altered regimen for specific tumour site and stage still remains widely open.
”To the ranch and back” – korzyÊci i koszty (powik∏ania)
niekonwencjonalnej radioterapii chorych na raka regionu g∏owy i szyi
C e l  p r a c y.  Ocena zysku terapeutycznego i kosztów (powik∏aƒ) niekonwencjonalnej radioterapii u chorych na raka regio-
nu g∏owy i szyi oraz krytyczne dyskusje wyników kontrolowanych badaƒ klinicznych.
M a t e r i a ∏  i m e t o d y k a.  Materia∏ obejmuje 4682 przypadki raka regionu g∏owy i szyi o ró˝nej lokalizacji i zaawansowa-
niu, w∏àczone do 12 najcz´Êciej kontrolowanych badaƒ klinicznych. Ocenà obj´to ró˝ne systemy frakcjonowania dawki, tj.
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Introduction
In conventionally fractionated radiotherapy for head
and neck cancers late radiation effects in normal tissues
were considered as the main threat to the quality of life
and survival and the major factor to decrease therapeu-
tic gain. Combination of RT with surgery and/or che-
motherapy may further increase the risk of late radiation
morbidity. As altered fractionation schedules are more
and more often explored in clinical trials, application
of more than one fraction per day of less than 2 Gy (hy-
perfractionation) produces increased sparing effects in
late responding normal tissues at the expence of an in-
creased incidence and severity of acute mucosal reac-
tions. Shortening of overall treatment time (OTT) by
acceleration the treatment may likely increase the risk
and severity of both acute and late morbidity, especially
if interfraction intervals are not long enough [1-5].
Biological rationale for improving treatment out-
come by altered fractionation stemmed from the recogni-
tion of accelerated tumour clonogen repopulation as an
obstacle to cure head and neck cancer. Mucosa epithe-
lium also demonstrates this phenomenon, however it ap-
pears to start somewhat sooner and to proceed faster
than in epithelial tumours. Exploiting differences in tu-
mour and normal tissues repopulation leads to altera-
tion of fractionation parameters to design accelerated
(AF), hyperfractionated (HF) or hybrid (AHF) regi-
mens. Integration of laboratory studies with bed-site ob-
servations was, and still is, the main objective of many cli-
nical trials in order to increase therapeutic benefit, main-
ly for advanced head and neck cancers. Usually, treat-
ment benefit is considered as an improvement of
long-term local tumour or locoregional control. However,
the assessment of benefit of altered radiotherapy sho-
uld properly include both cost-benefit and cost-expense
analysis.
Whilst cost-expense analysis needs formal and spe-
cific economical studies and the results may differ from
center to center, and from country to country, the bene-
fit is measured by the increase in locoregional control
(LRC) or disease-free survival (DFS) and weighted aga-
inst the costs. In this form of analysis, the costs mean do-
se-limiting normal tissue effects, which lower the LRC
benefit to the level-free of complications. This is defined
as a therapeutic gain, that is an increase in the rate of
uncomplicated cures. However, the main problem arises
which effects should be accounted for as limiting the
efficacy of dose escalation and the tolerance. The majo-
rity of clinical trials on altered radiotherapy show an in-
creased incidence and greater severity of acute mucosal
reactions. Thus, it has been claimed that acute morbidi-
ty should be considered as the main dose-limiting factor,
yet this appears to be based on belief rather than clinical
evidence. Acute confluent mucositis is a frequent com-
plication during RT but it is usually manageable and
12
przyspieszonego (AF), hiperfrakcjonowanego (HF) i hybrydowego (AHF). Jako kryteria zysku i kosztów przyj´to odpowiednio
3-letnie wyleczenie lokoregionalne oraz cz´stoÊç nast´powych odczynów póênych (CLE) i typowych póênych powik∏aƒ (LE).
W y n i k i. W niektórych trialach frakcjonowanie AF/AHF przynios∏o zysk terapeutyczny w grupie zaawansowanych raków, przy
braku zysku w stopniu TZ (CHART, EORTC 22791), podczas gdy w innym trialu (PMH) znamienny zysk terapeutyczny od-
notowano w grupie guzów o Êrednicy <4 cm. Szereg wàtpliwoÊci dotyczy b∏´dów selekcji i dozymetrycznych. Ocena powik∏aƒ
dostarcza wi´cej wàtpliwoÊci ni˝ w przypadku zysku LRC. Póêne efekty 2 i 3 stopnia sà cz´sto oceniane ∏àcznie, a kilka ró˝-
nych powik∏aƒ mo˝e wyst´powaç u jednego chorego. Póêne odczyny sà podawane w wartoÊciach bezwzgl´dnych, podczas gdy
LRC oceniane jest metodà aktualizacji. Ponadto ryzyko odczynów nast´pczych mo˝na jedynie dedukowaç z opublikowanych
wyników. A zatem LE (koszty) sà generalnie niedoszacowane. W niektórych trialach (Cairo, EORTC 22851) zysk jest pozor-
nie dodatni, ale dok∏adna ocena cz´stoÊci LE i CLE powoduje, ˝e trial staje si´ negatywny. Ostatecznie ogólny zysk terapeu-
tyczny niekonwencjonalnej radioterapii jest mierny, w granicach 0-15%. Analiza Znormalizowanych Dawek Ca∏kowitych, sko-
rygowanych dla zmiennej wartoÊci dawki frakcyjnej i ca∏kowitego czasu leczenia i szacowanych dla 50% prawdopodobieƒstwa
LRC (NTCD5o) wskazuje, ˝e przyj´ta Êrednia dawka 0,6 Gy/dzieƒ, równowa˝àca skutek repopulacji nowotworowych komó-
rek klonogennych. mo˝e byç zbyt niska i jej rzeczywista wartoÊç Êrednia wzrasta do 0,85 Gy/dz., a nawet 1,1-1,2 Gy/dz.
w czasie weekendów. Ponadto wydaje si´, ˝e okres spoczynkowy, poprzedzajàcy repopulacj´, mo˝e byç skrócony do 14-21 dni.
W n i o s k i. Wyniki przekonywujàco wskazujà, ˝e ograniczony zysk terapeutyczny mo˝e byç wynikiem limitowania dawek ca∏-
kowitych do poziomu tolerancji ostrego odczynu popromiennego, którego jednak nie mo˝na uznaç za czynnik ograniczajàcy
wysokoÊç dawki promieniowania. Stosowanie intensywnych schematów frakcjonowania, z u˝yciem dwóch dziennych dawek
frakcyjnych, z nieznacznà redukcjà dawki ca∏kowitej lub jej brakiem, mo˝na jedynie rozwa˝aç w przypadku eskalacji dawki
poza okres dni roboczych, tzn. z obj´ciem weekendów. Wyniki triali DAHANCA-7 i CAIR przemawiajà za s∏usznoÊcià tej kon-
cepcji. Jednak˝e, dla tak intensywnego leczenia, przedzia∏ bezpieczeƒstwa jest wàski i niewielkie zmiany ca∏kowitego czasu le-
czenia lub dawki mogà powodowaç, ˝e wzmo˝ony ostry odczyn mo˝e ulec niebezpiecznemu nasileniu, wywo∏ujàc nast´pczy
odczyn póêny, przekraczajàcy granic´ tolerancji.
Pomimo dwóch dziesi´cioleci szeroko zakrojonych badaƒ nadal pozostaje otwartym pytanie, jakie sà najbardziej skuteczne sys-
temy frakcjonowanego napromieniania dla poszczególnych lokalizacji i stopni zaawansowania raków regionu g∏owy i szyi.
Key words: altered fractionation, head and neck cancer, therapeutic gain, consequential and late effects
S∏owa kluczowe: zmienne frakcjonowanie, raki regionu g∏owy i szyi, zysk terapeutyczny, nast´pcze i póêne odczyny
popromienne
certainly not beyond the limit of tolerance as the price
for cure [3]. Above all, it is transient. Therefore, the cli-
nically relevant criterium of acute tolerance should like-
ly be determined by consequential late effects (CLE)
which have to be avoided, if possible. Necrosis and con-
secutive fibrosis are clearly beyond the limit of toleran-
ce because they are difficult to manage therapeutically
and may lead to permanent morbidity [1]. For these
reasons, both rates of the LE and the CLE have been
chosen as the costs of altered RT and weighted against
the LRC or DFS benefit to establish overall therapeutic
gain.
Material and methods
C l i n i c a l  d a t a
For the present analysis the data sets of 12 clinical trials most
often cited in the literature, including all together 4682 cases
of head and neck cancer, have been selected. They represent all
sites and stages of head and neck cancer and wide variety of al-
tered dose-fractionation schedules, i.e. accelerated (AF), hy-
perfractionated (HF) of hybrid accelerated – hyperfractiona-
ted (AHF), given as a continuous, split-course, concomitant bo-
ost or escalated radiation treatment [6-18]. There are 9 trials
on 5-days/week treatment, one trial on 6-days/week and 2 trials
on 7-days/week treatment. In control arm (c) conventional
fractionation with 1.8 Gy or 2.0 Gy per fraction, once-a-day
(qd) was used, except PMH Toronto and RTOG 8809 trials whe-
re accelerated-like 51 Gy in 28 days or concomitant boost of
70.5 Gy in 42 days respectively, were used as a control regi-
mens.
D o s e  N o r m a l i z a t i o n
Because of large variation in total dose (Di), dose per fraction
(di) and overall treatment time (OTT), total dose was normali-
zed to that (NTD) which would have been isoeffective if given in
2 Gy fractions, using formula [5]:
NTD = Di [(α/β + di) / (α/β + 2.0)],
where α/β ratio of 15.0 Gy was used.
If there was difference in the OTT between two arms of a given
trial the NTD was additionally corrected for repopulation using
Drep of 0.6 Gy/day [5].
To check the importance of the assumed α/β ratio to the
conclusions drawn, alternative series of calculations were made
using an α/β values between 10 Gy and 15 Gy, which are wi-
thin the range commonly used in many studies. It was found
that relative to a value of 15 Gy, an α/β ratio of 10 Gy only sligh-
tly increases the adjustment made to the total dose.
From the NTD values for altered (exp) and conventional
(c) arm the difference (∆NTD) was calculated as follows:
∆NTD = NTDexp – NTDc
and it was related to the LRC benefit (at least-3 year locoregio-
nal control).
C a l c u l a t i n g  T C D 5 0 v a l u e s
To intercompare LRC rates which usually differed from 50%,
TCD50 values were calculated based on assumptions regarding
cell killing in which the slope of the dose response curve re-
flects an effective Do of 5 Gy. Change in dose to achieve 50% cu-
re (Pcure 0.5) was calculated from:
NTCD50 = NTDx + n • effDo
where n = Ln (Ln 0.5/Lnx)
The value of 5 Gy for effDo rather than a lower value was
chosen on the assumption that there would be heterogeneity of
tumour and treatment characteristics affecting the slope of tu-
mour control probability curves.
NCTD50 values were plotted as a function of overall treat-
ment time (OTT) and isoeffective dose-time curve was estima-
ted.
B e n e f i t  e n d - p o i n t s
Locoregional control rate (at least 3-years) was either clearly do-
cumented or it has been subtracted from the respective LRC
curves, and they were used to calculate LRC benefit.
C o s t s  e n d - p o i n t s
For the present analysis, confluent mucositis (CM) is defined as
severe mucosal reaction, and it corresponds with grade 4 of the
EORTC scale or with Dische score >13. Increase in the inciden-
ce of the CM was calculated as a difference in the CM between
experimental and control arm. Overall costs of altered regimes
was estimated as a relative increase or decrease in the LE rates
(including the CLE incidence) for experimental arm as compa-
red with control, using formula:
COSTS (∆LE) = LEexp – LEconv
T h e r a p e u t i c  g a i n
Therapeutic gain (TG) means an improvement in uncomplicated
locoregional control (≥3 yrs.) and it was calculated from:
TG = TGexp – TGconv,
= LRCexp • (1 – LEexp) – LRCconv • (1 – LEconv),
Relative TG is given as a ratio of TGexp/TGconv
Incidence of severe late effects (severe fibrosis, necrosis or bone
fracture, required surgical intervention and/or threatening quali-
ty of life) were documented as absolute numbers, rates or it was
subtracted from the published curves of accumulated risk of LE
or of late effect-free survival. However, the accuracy of the rate
of LE considered as tolerance-limiting is uncertain to some
extent because in some papers grade 3 effects were counted to-
gether with grade 2, and some figures are not interpretable as
such, since several late events may occur in the same patient.
Thus, in some situations overall costs might likely be under- or
overestimated.
Consequential late effects (CLE) are morphologically-like
typical late sequelae, and they can be recognized if developed
early (≤6 months) after completing the treatment, and seconda-
rily after the initial very severe confluent mucositis (grade 4,
EORTC). If the CM healed after completing the treatment the-
re is a short latency period to the onset of CLE, or if it is not,
acute CM directly progresses into the CLE. For the present
analysis the CLE clearly documented were included, and also
those which characteristics of acute effects, the nature, and the
onset likely allow to suspect they are consequential.
Results
B e n e f i t s  v s .  c o s t s
The results of 12 clinical trials are listed in Table I.
C a i r o  t r i a l  (Tab. I-a): At the first glance AHF
postoperative regimen gives 15% gain in the LRC as com-
13
14
Ta
b.
 I
. B
en
ef
it
s 
an
d 
co
st
s 
of
 th
e 
se
le
ct
ed
 a
lt
er
ed
 r
ad
io
th
er
ap
y 
fo
r 
he
ad
 a
nd
 n
ec
k 
ca
nc
er
N
o
Sc
he
du
le
 a
nd
 fr
ac
tio
na
tio
n
N
o.
∆N
T
D
(x
x)
2.
0
T
I
B
en
ef
it
C
os
ts
T
he
ra
pe
ut
ic
A
ut
ho
r
D
os
e
/ f
ra
ct
io
ns
 / 
da
ys
pt
s.
G
y
(h
ou
rs
)
L
R
C
C
M
C
L
E
L
E
ga
in
5 
da
ys
/w
k.
(a
)
A
H
F
 (
t.i
.d
.)
42
G
y/
30
fr
./1
1d
.
56
4.
9 
G
y
4
↑
15
%
↑
25
%
?
↓
23
%
14
.5
%
A
w
w
ad
 (
6)
C
ai
ro
(c
)
50
G
y/
25
fr
./3
5d
.
*
(5
4%
 v
s.
39
%
)
(6
4%
 v
s.
87
%
)
(1
9.
5 
vs
.5
%
)
(b
)
A
F
 (
b.
i.d
.)
66
G
y/
33
fr
./2
5d
.
82
12
.0
 G
y
6
↑
14
%
↑
46
%
5%
↑
15
%
3.
2%
Ja
ck
so
n 
et
 a
l. 
(1
5)
V
an
co
uv
er
 
(c
)
66
G
y/
33
fr
./4
5d
.
*
(7
0%
 v
s.
56
%
)
(c
)
A
H
F
 (
b.
i.d
.)
58
G
y/
40
fr
./2
8d
..
33
1
3.
5 
G
y
6
↑
9%
↑
14
%
-
↓
6%
10
.4
%
C
um
m
in
gs
 (
9)
PM
H
(c
)
51
G
y/
20
fr
./2
8d
*
(4
8%
 v
s.
39
%
)
(d
)
A
H
-S
 (
t.i
.d
.)
72
G
y/
45
fr
./3
5d
.
51
2
8.
7 
G
y
4
↑
13
%
↑
36
%
13
%
↑
10
%
6.
5%
H
or
io
t e
t a
l.(
14
)
E
O
R
T
C
 2
28
51
(c
)
70
G
y/
35
fr
./4
9d
.
*
(5
9%
 v
s.
46
%
)
(f
or
 L
E
F
S
- 2
%
↑
21
%
)
(e
)
A
H
-C
B
 (
b.
i.d
.)
 
72
G
y/
42
fr
./4
2d
.
79
5.
4 
G
y
6
↑
13
%
↑
18
%
-
no
 d
iff
.
13
%
A
ng
 e
t a
l. 
(7
)
ar
m
 I
II
-la
st
 2
1 /
2
w
k.
6
(7
9%
 v
s.
66
%
)
(c
)
ar
m
 I
 +
II
 –
 fi
rs
t 2
1 /
2
w
k.
+
 tw
ic
e-
a-
w
ee
k
(f
)
A
H
-S
 (
b.
i.d
.)
vs
. C
B
67
.2
G
y/
42
fr
./4
2d
.
70
(4
.9
 G
y
6
↑
16
%
↑
7%
-
↑
11
%
15
.5
%
Fu
 e
t a
l. 
(1
2)
R
T
O
G
 8
80
9
70
.5
G
y/
41
fr
./4
2d
.
*
(4
7%
 v
s.
31
%
(g
)
H
F
 (
b.
i.d
.)
80
.5
G
y/
70
fr
./4
9d
.
32
0
6.
5 
G
y
4 
– 
6
↑
19
%
↑
18
%
-
↑
2.
9%
16
.2
%
H
or
io
t e
t a
l. 
(1
3)
E
O
R
T
C
 2
27
91
(c
)
70
G
y/
35
fr
./4
9d
.
(5
9%
 v
s.
40
%
)
(h
)
H
F
-A
H
F
 (
b.
i.d
)
H
F
81
.6
 G
y/
68
 fr
./4
8 
d.
10
73
7.
7 
G
y
6
7.
6%
↑
20
%
-
↑
5%
4.
4%
A
ng
, F
u 
(8
)
R
T
O
G
 9
00
3
(5
3.
7%
 v
s.
46
.1
%
)
A
H
F
-S
67
.2
G
y/
42
fr
./4
2d
.
no
 d
iff
.
6
1.
6%
↑
16
%
-
↑
3%
N
O
 (
0.
06
%
)
(4
7.
7%
 v
s.
46
.1
%
)
A
H
F
-C
B
72
.0
G
y/
42
fr
./4
2d
.
6.
6 
G
y
6
8.
1%
↑
24
%
-
↑
3%
5.
9%
(c
)
70
.0
G
y/
30
fr
./4
8d
.
(5
4.
2%
 v
s.
46
.1
%
)
-
*
-
-
-
-
-
(i
)
A
H
F
 (
b.
i.d
.)
A
H
F
59
.4
G
y/
35
fr
./2
4d
.
35
0
6
3%
↓
3%
D
en
ha
m
 (
10
)
T
R
O
G
 9
10
1
(c
)
70
.0
G
y/
35
fr
./4
7d
.
2.
5 
G
y
*
(5
4%
 v
s.
51
%
)
↑
30
%
-
no
 d
iff
.
6 
da
ys
/w
k.
(k
)
A
F
 (
q.
d.
)
66
G
y/
33
fr
./3
9d
.
79
1
4.
2 
G
y
24
↑
9%
↑
20
%
-
no
 d
iff
.
9%
O
ve
rg
aa
rd
 e
t a
l.(
17
)
D
A
H
A
N
C
A
 7
/5
(c
)
66
G
y/
33
fr
./4
6d
.
*
(6
6%
 v
s.
57
%
)
[(
12
%
 fo
r 
T
 s
itu
]
7 
da
ys
/w
k.
(l
)
A
H
F
(t
.i.
d.
)
54
G
y/
36
fr
./1
2d
.
91
8
2.
4 
G
y
6
5%
↑
30
%
-
↓
4%
6.
5%
D
is
ch
e 
et
 a
l. 
(1
1)
C
H
A
R
T
(c
)
66
G
y/
33
fr
./4
5d
.
*
(4
5%
 v
s.
40
%
)
(m
)
A
F
 (
q.
d.
)
70
G
y/
35
fr
./3
5d
.
10
0
14
.0
 G
y
24
45
%
↑
36
%
11
%
↑
6%
36
.5
%
Sk
∏a
do
w
sk
i e
t a
l.(
18
)
C
A
IR
(c
)
70
G
y/
35
fr
./4
9d
.
(8
.4
)
*
(8
2%
 v
s.
37
%
)
[A
F
- a
cc
el
er
at
ed
; A
H
F
 –
 a
cc
el
er
at
ed
/h
yp
er
fr
ac
tio
na
te
d;
 H
F
 –
 h
yp
er
fr
ac
tio
na
te
d;
 s
 –
 s
pl
it;
 C
B
 –
 c
on
co
m
ita
nt
 b
oo
st
; q
.d
. –
 o
nc
e-
a-
da
y;
 b
.i.
d.
 –
 tw
ic
e-
a-
da
y;
 t.
i.d
. –
 tr
ic
e-
a-
da
y;
 c
 –
 c
on
tr
ol
 g
ro
up
; *
 –
 c
on
ve
nt
io
na
l 2
4h
in
te
rf
ra
ct
io
n 
in
te
rv
al
; *
* 
– 
se
e 
fo
ot
no
te
 in
 th
e 
te
xt
]
pared with conventional control. When the LE costs are
accounted for an overall therapeutic gain (TG) is still
close to 15%, suggesting that the AHF might relatively be
even 3.9 times more effective than conventional regimen,
(19.5% / 5%). However, unacceptably high rates of the
LE make the TG rate in both arms far below the initial
LRC level in the control arm. Moreover, there were two
times more patients with adequate surgical margins in
control group. If one would agree that it is a crucial pro-
gnostic factor for treatment outcome, specific analysis
may likely suggest no gain at all for this trial.
Va n c o u v e r  t r i a l  (Tab. I-b): Overall treatment ti-
me (OTT) is the only variable in this trial, and shortening
the OTT by 20 days gives 1.2% benefit in the LRC for
each 1 Gy increase in effective NTD2.0, suggesting fairly
shallow dose response curve (γ= 0.78) probably due to
heterogeneity of tumour sites and stages. The LRC bene-
fit is, however, neutralized by 15% higher costs (late toxi-
city) in the AF arm, and thus overall therapeutic gain de-
creases to only 3.2%, and suggests no advantage of the
AF schedule. The trial was discontinued after randomisa-
tion of 82 pts.
P M H  v s .  C H A RT  ( Tab. I-c,l): The PMH with
fractionation given b.i.d. in 4 weeks (5 days/week) and
the CHART with t.i.d. in 12 days (7 days/week) with es-
sentially the same dose per fraction (1.45-1.5 Gy) are
compared. In both trials the LE costs in the altered arm
were lower than in the control, and thus therapeutic gains
(TG) were slightly higher than LRC benefits. For both
trials, each 1 Gy increase in the NTD2 produces 1.7-1.9%
improvement in the TG. It is however, intriguing that the
CHART showed higher benefit for advanced laryngeal
tumours, and no advantage for T1-2 and for oral cavity,
oropharynx and hypopharynx, whereas the PMH produ-
ced significant LRC benefit of 12% for small tumours
(<4 cm), and no gain for larger ones (>4 cm). Further-
more, the best improvement for hypopharyngeal tumours
was noted although present in all sites. The results of
both trials suggest that a large reduction of the total dose,
to circumvent mucosal reaction, associated with drastic
shortening of treatment time might neutralize the poten-
tial benefit of accelerated schedules.
E O RT C  2 2 8 5 1  (Tab. I-d): This trial explored the
t.i.d. accelerated hyperfractionation with shortening the
OTT by 24 days, and total dose similar to that in conven-
tional arm. The difference in effective NTD2.0 was 8.7 Gy
producing 13% LRC benefit. For unfavourable T & N pat-
terns (any T, N2-3, T4 any N) LRC benefit in favour of the
AHF-S arm was even higher (18%), however with no ad-
vantage for nodes, survival and specific survival. Oral cavi-
ty and oropharyngeal tumours did significantly worse.
Evaluation of the costs leads to confusing interpreta-
tion. Overall incidence of the LE of 10% higher in the
AHF-S arm corresponds with the decrease in therapeutic
gain to 6.5%. However, when late-effect free survival is
accounted for the difference of 21% in disfavour of AHF-
-S gives no gain at all (-2%). Although consequential late
effects are not directly defined and counted, it looks that
13% of severe protracted grade 3 mucosal sequelae might
likely be considered as the CLE. Therefore, both costs
and therapeutic gain are uncertain because the incidence
and severity of late effects (grade 2 and 3 are groupped
together) are not interpretable as such, since several
events may occur in the same patient. Although, the
AHF-S might be beneficial for some advanced tumours,
such intensive t.i.d. schedule with insufficient 4-h inter-
fraction intervals appears to be too toxic.
RT O G  8 8 0 9 ,  M DAC C - C B ,  RT O G  9 0 0 3
(Tab. I – e,f,h): Comparison of these three the US trials is
quite surprising. The RTOG 8809 trial published in 1995
was designed to establish the patient tolerance to each of
the two (split-course vs. concomitant boost) altered regi-
mens rather than to test for differences between them.
However, it showed, although not significant, but still
substantial 16% LRC benefit in favour of the AH-S arm
referred to the ∆NTD2.0 of 4.9 Gy. Perhaps due to the
same dose per fraction in two arms no significant increase
and difference in late toxicity has been noted, and perma-
nent grade 4 late toxicity was 6% for the split and 7%
for the concomitant boost.
A few year earlier the MDACC tested efficacy of
the concomitant boost (CB) in the three-arm trial. It sho-
wed 13% LRC benefit in favour of the CB given du-
ring the last 2-21/2 wks as compared with the CB given
either twice a week during the basic course or during the
first 2-21/2 wks There was no difference in costs between
three arms, with only a slightly higher (18%) incidence
and severity of acute mucosal reactions when the boost
has been given during the first 2-21/2 wks. However, what
is surprising is that the LRC rate of 79% was about 2.5 ti-
mes higher than in the CB arm of the RTOG 8809 al-
though in both trials almost the same tumour sites and
stages were included.
Recently reported RTOG 9003 trial has compared
three different altered regimens with conventional fractio-
nation. It showed 7- 8% LRC benefit in favour of hyper-
fractionation (HF) and concomitant boost (CB) with no
advantage of the split-course (S). Because the costs (LE)
were slightly higher in altered arms, overall therapeutic
gain decreased to 4.4% and 5.9% for the HF and CB re-
spectively, and almost to zero (0.07%!) for the S. No ad-
vantage for the split-course is not surprising because the
effective NTD2.0 was almost the same as in the control. In
fact, the LRC rates for the split-course regimen in the
RTOG 8809 and RTOG 9003 were exactly the same.
What is, however, confusing and difficult to explain, is
why NTD2.0 in the RTOG 9003 higher than in the
MDACC produced 1.5 times lower LRC benefit and the-
rapeutic gain. It is also difficult to understand why in the
RTOG 8809 the LRC benefit in favour of the split regi-
men has been achieved by the NTD dose of about 5 Gy
lower than that for the CB. It seems that even tumour he-
terogeneity and selection bias might unlikely explain the-
se opposed results and conclusions.
E O RT C  2 2 7 9 1  (Tab. I-g): In contrast to
other trials this one includes fairly homogenous group
of T2-3N0-1 oropharyngeal cancers. For the first time, the
results have shown convincing advantage of hyperfrac-
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tionation with overall LRC benefit of 19% as the result of
increase in the NTD2.0 of 6.5 Gy. For T3 tumours LRC be-
nefit was even of 35%, but not for T2 tumours and all
nodes. Once again, it is difficult to quantify the costs sin-
ce late effects (grade 2 and 3) were groupped together
and several events may occur in he same patients. Ne-
vertheless, overall difference in the LE rates between two
arms was of 2.9% (8.8% vs. 5.9%) resulting in therapeu-
tic gain of 16%. This TG was about 3.5 higher than the re-
spective gain for the HF arm in the RTOG 9003 trial. It is
difficult to answer whether it simply reflects more advan-
ced tumours in the RTOG than in the EORTC trial.
T R O G  9 0 0 1 :  The Trans-Tasman trial used the
AHF regimen of 1.8 Gy fractions given b.i.d. in the OTT
shortened by 23 days. Total dose was only slightly reduced
to 59.4 Gy and it is almost equivalent to conventional 70
Gy in 35 fractions in 47 days. The LRC rate in both arms
was almost identical and close to 50% (3% LRC benefit
in favour of the AHF). The most important point to
emerge from the results is that by shortening the OTT by
about 3 weeks a total dose of 59.4 Gy given b.i.d. is isoef-
fective to 70 Gy in 7 weeks, and they both can be interpre-
ted as TCD50. For the first time, acute and late effect as
the costs of this trial were precisely quantified [1], and the
results showed that although the acute CM was more fre-
quent (30%) in AHF arm they have been quite well tole-
rated by patients. The important observation is the dura-
tion of CM was inversely related to the time to onset of
the reaction. For both arms similar hazard ratio for grade
3 late effect was at the range of 1.20-1.22. Acute and late
effects were observed more commonly in patients with
oral cavity and oropharyngeal tumours.
DA H A N C A- 7  a n d  C A I R  (Tab I.-k,m): These
two trials tested the concept that simple continuous cour-
se using 2 Gy daily fractions, 6 or 7 days, instead of 5
days a week, may likely to offer at least the same benefit
with less late effects.
The DH-7 trial showed a significant 9% LRC be-
nefit for 6 days/week regimen independent on tumour
site and stage, however, with no advantage for nodes.
For T-site only the LRC benefit was of 12%. Analysing
the costs an increase (20%) in acute (all were reversible
and healed within 2 months after RT) but not in late toxi-
city has been observed. Thus, giving 6 days/week treat-
ment with moderate shortening of the OTT by one-week
resulted in a significant therapeutic gain of 9-12%. Fur-
thermore, well and moderate differentiated tumours ap-
peared to gain more from accelerated regimen then un-
differentiated tumours (27% vs. 10% in gain the LRC).
The issue related to tumour differentiation is intriguing
and becomes one of the important target for future stu-
dies. The 6 days/week regimen has become standard ra-
diotherapy for head and neck cancer in Denmark.
The CAIR made one step further by giving 7 frac-
tions in 7 days and shortening the OTT by 2 weeks. It
resulted in the LRC benefit of 45%. Although such une-
xpectedly high benefit might be uncertain and questio-
nable, it has to be pointed out that the benefit is related
only to homogenous group of T3-4N0-1 oral cavity and
oropharyngeal tumours. In contrast to DH-7, in the AF
arm of the CAIR, when 2 Gy fractions were used, 22% of
consequential late effects have developed relatively early
during follow-up. For that fraction size therapeutic gain
decreases to only 30%. However, when dose per fraction
was lowered to 1.8 Gy no more CLE occurred, and overall
late effects (including CLE) were only 6% higher than
in control arm. Finally, therapeutic gain of 7 days/week re-
gimen is 36.5%. Despite the risk of CLE, acute reactions,
although more frequent in 7 days/week arm, have not be-
en dose-limiting, but tolerable by patients. Therefore, 7
days/week regimen became in Gliwice a standard treat-
ment for T3-4N0-1 oral cavity and oropharyngeal tumo-
urs.
Discussion
This review of the most often cited trials on unconventio-
nal fractionation likely suggests that altered regimens are
probably not universal „golden key” for radiotherapy for
advanced head and neck cancer, and still it can rather
be considered as a „Holly Grail” because too many qu-
estions remain unanwsered.
L RC  b e n e f i t
Although there is general trend of the LRC benefit in
favour of different combinations of accelerated and/or
hyperfractionated regimens, the detailed analyses lead
to considerable confusions. In some studies the AF/AHF
regimens were superior for advanced tumours (CHART,
EORTC 22791) but not for T2, whereas in others signifi-
cant benefit was noted for tumours smaller than 4 cm
(PMH). Despite the majority of trials cover all tumour si-
tes and stages, the PMH trial has documented the best
LRC benefit for hypopharyngeal tumours, whereas
CHART in contrast, showed a significant improvement
for T3-4 laryngeal cancer with no advantage for oral cavi-
ty, oropharynx oral hypopharynx. There is substantial evi-
dence of higher LRC benefit for specific subgroups of
patients than overall improvement. The EORTC 22851
trial noted the LRC benefit for T4 tumours about 6% hi-
gher than overall gain, marginal benefit for T2-3N0-1, and
the worst prognosis for oral cavity and oropharynx. In
DAHANCA-7, also 6% higher benefit was noted when T-
-site was accounted for the analysis. In the two trials it was
noted [11,17], that well differentiated tumours respon-
ded better to accelerated regimens than poorly differen-
tiated. This feature may closely be related to the normal
cells from which the tumours have their origin. Thus, the
ability of squamous epithelium to rapidly proliferate in re-
sponse to radiation injury may be retained by well and
moderate differentiated but lost in the poorly differentia-
ted cancers.
Comparison of the three US trials reveals a few un-
certainties. The RTOG 8809 showed the LRC advantage
of the AH-split-course over concomitant boost (CB),
whereas in the RTOG 9003 no gain at all was noted for
the split-course altered regimen and the CB was found
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the most effective, supporting earlier results of the
MDACC trial. However, it is difficult to explain why the
LRC benefit of the CB was about 1.5 times lower in the
RTOG 9003 than in the MDACC although dose fractio-
nation pattern was the same, and similar T-sites and stages
have been recruited to both trials. Similar uncertainty
arises comparing the HF arm of the RTOG 9003 with
the EORTC 22791 which reported about 2.5 times hi-
gher LRC benefit than that noted in the US trial.
The next potentially surprising point to emerge is
that overall or specific LRC benefit in all trials is related
to an average (median) total dose and fractionation pat-
tern, although in some trials a wide range of dose is used
[14]. If a total dose is, for example, in the range of 70-76
Gy, and dosimetric error is of about 5% (this parameter is
almost never reported in the published reports) it gives
the dose range even wider, from 66.5 Gy to 79.8 Gy. Thus,
such large scale of dose reflects a whole range of dose-re-
sponse curve rather than a single LRC rate-dose point,
which in fact, is a basic assumption, for a given trial. It se-
ems likely that even within homogenous T-site and stage
subgroups, patients receive different total doses and ove-
rall treatment times. Therefore, overall LRC benefit is
only an average value reflecting unknown variations in
LRC rates and in radiation doses. Moreover, the imbalan-
ce of case distribution into treatment arms concerning
predictive parameters is crucial for validity of the interpre-
tation of the results with regard to treatment outcome,
and thus benefit of altered fractionation might be undere-
stimate in some trials or overestimated in others.
C o s t s  a n d  t h e r a p e u t i c  g a i n
Interpretation of the costs (acute and late morbidity) is
even more uncertain than that of the LRC benefit. Obvio-
usly causion is necessary in interpreting acute mucosal
reactions, but although an increase in the incidence and
severity of acute mucositis (CM) was usually noted for
altered regimens, the most severe reactions have been
transit and usually subsided within 2-3 months after com-
pleting the treatment (Fig. 1). Thus, they do not seem to
be dose-limiting. What important is pointed out by Den-
ham et al. [1] is that duration of the CM is inversely rela-
ted to the time to onset of the reaction, that means, the
longer acute CM lasts (>20 days) the earlier it develops.
The authors also noted that duration of the CM might be
a good quantitative surrogate for the level of acute muco-
sal cellular depletion caused by a fractionation regimen.
There is a good clinical evidence that late mucosal
reactions occur in part as a consequence of acute denuda-
tion of squamous epithelium [1]. The TROG 9101 and
CAIR data show that the acute CM lasted longer than 3
weeks strongly correlates with the risk of consequential la-
te effects (CLE). This raises concern that late normal tis-
sue sparing from hyperfractionated regimens may be off-
-set by increased risk of the CLE. According to Denham
et al. [1] the hazard ratio for grade 3 late reactions in the
TROG 9101 was 1.2 for each increasing week spent at
the CM level. Nguyen and Peracchia studies [19, 21] on
highly intensive short accelerated regimens support this
suggestion. Also escalated accelerated regimens tested
in phase I studies by Kaanders et al. [16] and Harari et al.
[2] produced unacceptable incidence of the CLE. All the-
se regimens have been abandoned, and never entered in-
to phase III trials.
There is convincing evidence that both consequen-
tial (CLE) and typical late (LE) normal tissue reactions
should be considered as a true dose-limiting events (co-
sts) of altered radiotherapy (Fig. 1, black area within
the graphics symbolizes CLE). Although it is difficult
to separate CLE from LE and they both might be very
heterogeneous in their nature and in morphologic pat-
terns, and difficult to quantify, the tools used in clinical
trials to quantify late effects have not generally been
validated. Thus, many inconsistencies arise from inconc-
lusive collection and reporting of late effects. They are
usually reported as a composite of grade 2 and 3, where-
as only the grade 3 reactions can be regarded as dose-li-
miting. In the EORTC 22791 no separate information
was given about the relevant endpoint for late reactions.
In the EORTC 22851 the CLE of 13% can only be dedu-
ced indirectly from signs and duration of the acute ef-
fects.
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Fig. 1. Incidence of acute confluent mucositis (CM, IVo) against maximal
Relative Accumulated Normalized Dose per week (rANDmax).
Number in graphics gives a week in which rANDmax reaches the highest
value. The rANDmax was normalized to 2.0 Gy fraction regimen using α/β
of 15.0 Gy and corrected for normal mucosal repopulation using on ave-
rage of 1.0 Gy/day and the lag period of 14 days. Relative ANDmax was
calculated as a ratio of maximal value of AND for altered regimen and
conventional AND for the respective week of treatment. Conventional
AND1,AND2, AND3,... AND6 equal 10 Gy, 20 Gy, 23 Gy,... 29 Gy. Five
additional data sets are included to show the risk of consequential late ef-
fects (black area within the graphics): [fractionation: half-circle –
3 days/wk., circle – 5 days/wk., triangle – 6 days/wk., square – 7 days/wk.]
In contrast to tumour response most often reported
as an actuarial analysis, late reactions are mainly given as
a crude data yielding underestimation of complication
incidence. The increase in total dose from 70.0 Gy to
80.5 Gy (in fact, it is only 6.5 Gy increase in effective
NTD2.0) leads in the EORTC 22791 trial to the increase
in the LRC for T3-4, but not for T2. However, the benefit
for T3 tumours might partially be compensated for, be-
cause grade 3 late effects probably increased simulta-
neously. On the other hand, the benefit for T2 tumours
can not be ruled out, since normal tissue data were not
broken down by tumour stage. Thus, therapeutic gain as
the result of the LRC benefit weighted against the costs
remains uncertain, and it is clearly illustrated by the re-
sults of the EORTC 22851 trial. If the reported 10% in-
crease in overall rate of late effects is weighted against
LRC benefit of 13% therapeutic gain is of 6.5%, whilst
the late effect – free survival is accounted for as an end-
-point, therapeutic gain becomes negative.
The results of Cairo trial are also misleading
(Tab. I). Almost no decrease in therapeutic gain (14.5%)
is noted when the LRC benefit is weighted against the
costs, but in fact, the TG in both arms is far below the
control LRC suggesting the trial might also be considered
as „negative”.
Finally, analysis of acute and late effects in the
TROG 9101 trial show that in contrast to severe mucosal
reactions being site-independent, late effects developed
less frequently in hypopharynx and larynx than in oral
cavity and oropharynx. Thus, tumour site heterogeneity,
mainly in the multicenter trials, and its imbalance in favo-
ur of one arm may additionally be the cause of over- or
underestimation of the therapeutic gain, independently on
dose escalation.
Among the reviewed trials, the CAIR shows the hi-
ghest LRC benefit in favour of 7 days/week regimen, and
even if late effects are accounted for an overall thera-
peutic gain remains unexpectedly high. Although it might
be true such results should carefully and critically be inter-
preted because if a trial is small and it reaches signifi-
cance, then the observed difference might likely be overe-
stimated.
I m p o r t a n c e  o f  o v e r a l l  t r e a t m e n t  t i m e
( O T T )
The results of all trials clearly confirm the radiobiological
concept that overall treatment time reflecting accelerated
tumour clonogen repopulation is a major determinant of
the LRC benefit in radiotherapy for advanced head and
neck cancer. Although it seems obvious, therapeutic gain
associated with OTT contraction can only be guessed in-
directly because of variation in fractionation parameters.
Figure 2 shows an increase in the therapeutic gain (TG)
with shortening of the OTT. This comparison shows that
no single value of the TG per one day shortening of the
OTT can be calculated. CAIR and DAHANCA-7 trials
where change in the OTT was the only variable imply
1.5-2.5% increase in the TG per each one day contraction
of the OTT in the range from 7 to 5 weeks. However,
when the OTT was dramatically shortened from 6-7 we-
eks to 2-3 weeks, the increase in TG related to change in
the OTT becomes very small, i.e. 0.1-0.4% / 1 day contrac-
tion. It can be the result of too large reduction of the to-
tal dose to circumvent mucosal reaction associated with
drastic reduction of treatment time, which may neutralize
the potential benefit of treatment acceleration.
Accelerated arms in the EORTC 22851 trial and in
the CAIR differ by the only fact that the former is „week-
end free” and the latter is „weekend busy” treatment.
Difference in the TG for altered arms of both trials is
19.8% (70.5% vs. 50.7%). Assuming that tumour repopu-
lation begins around day 21 this difference gives about
5% increase in the TG per each one day of the weekend.
Because such high increment in the TG seems unreali-
stic, another explanation might be that accelerated repo-
pulation begins earlier, that means around day 14. It wo-
uld give an increase in the TG of 3.3% / 1”weekend day”.
Thus, the suggestion there is no reason to shorten overall
treatment time to less than 4 weeks does not seem plau-
sible.
Although all the above speculations might be more
or less acceptable, it seems the OTT might not be the
only important and independent factor influencing thera-
peutic gain. Despite the OTT contraction, it is also impor-
tant how intensively daily dose (one, two or three daily
fractions) is accumulated during the course of treatment,
and how large is reduction of total dose. The TROG 9101
trial shows that for 4-week treatment total dose of about
60 Gy is almost equivalent to 70 Gy given in 7-weeks,
and they both are close to the TCD50 values.
I m p o r t a n c e  o f  t o t a l  d o s e
Comparison of LRC benefit for different altered regi-
mens becomes useless and misleading if it is simply rela-
ted to physical total dose because of wide variation in si-
ze of dose per fraction, number of daily fractions, and in
overall treatment time. At the first glance, the same loco-
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Fig. 2. Therapeutic gain (LRC benefit – late effect costs) against overall
treatment time. Only trials with difference in OTT between arms are
included.
[black point represents control group; graphics and letter symbols as in
Tab. I]
regional control rates of 47-48% for the PMH and the
RTOG 8809 have apparently been produced by quite dif-
ferent doses of 58 Gy and 67.2 Gy. However, they become
almost the same of about 56 Gy if corrected for change in
dose per fraction and in overall treatment time, assuming
the onset of accelerated repopulation on day 28. In the
TROG trial physical dose of 70 Gy in 47 days is higher
than 59.4 Gy in 24 days, however they both are biological-
ly isoeffective producing almost the same LRC rate of
51% and 54%. In contrast, in the DAHANCA-7 trial the
same physical total doses of 66 Gy in both arms produced
different LRC rates of 66% and 57%, since they diffe-
red biologically by at least 4.2 Gy.
All the above examples explain why physical total
dose should be converted into Normalized Total Dose
(NTD2.0) if the treatment efficacy is compared. Scatter-
gram of the LRC benefits and costs plotted as a function
of the NTD2.0 (Fig. 3) shows that there is no single and
simple relationship between the TG and the NTD2.0, and
at least two subsets of the LRC costs-dose relationship
can be seen.
The upper panel A collects the trials with high or in-
creased total dose and with pronounced shortening of
overall treatment time, that means, very intensive regi-
mens. For this subset an average increase of LRC bene-
fit is of the about 2.3-2.5% per each 1 Gy increment in
the NTD2.0. The costs lower therapeutic gain to 1.25% /
1 Gy increment in the NTD2.0. The lower panel B re-
presents less intensive altered regimens, without or with
slight reduction in overall treatment time and it shows
much smaller increase in the LRC benefit of about 0.55%
/ 1 Gy increase in the NTD, and almost no therapeutic
gain.
The important point to emerge from this analysis is
that both LRC benefit and overall therapeutic gain si-
gnificantly depend on dose intensity delivered in a given
time. The longer OTT is used (less contraction) the more
intensive dose fractionation should be used. Any com-
promise in dose reduction due to pronounced shortening
of the OTT usually dilutes the expected therapeutic gain.
The CHART results support this relationship.
The second important conclusion would be that any
treatment end-point should not be considered in terms of
dose intensity separately from of overall treatment time,
because the power of these two parameters is closely in-
terdependent. Additionally, Figure 3 shows a tendency
of almost the same „cost-area” (area between solid and
dotted line) for two subsets of data independent on chan-
ges in dose and in time. It suggests that the size of thera-
peutic gain might seriously be constrained by the false
intention to limit total doses to the level that do not exce-
ed acute mucosal tolerance which seems to be a myth ra-
ther than proved by clinical evidence. On the other hand,
because our knowledge on consequential and late effects
remain unprecise and fragmentarical true dose-limiting le-
vel is still uncertain.
T h e r a p e u t i c  g a i n  v s .  i n c r e a s e  i n  e f f e c -
t i v e  N T D
Assuming that, in altered fractionation change in dose
and in time depend on each other and they should be
counted together, the LRC benefit and therapeutic gain
for various trials is weighted against an increase in the
NTD* (corrected for the OTT) for experimental arm as
compared with control (Fig. 4). It shows an average incre-
ase in the LRC benefit of about 3% per each 1 Gy incre-
ment in the effective NTD2.0 and slightly less (about
2.5%) in therapeutic gain. For very short regimens the
costs of altered schedules appear to be even lower than
for conventional standard.
It is interesting to note that on Figure 4 four data po-
ints are far below the estimated curve. In two trials
(EORTC 22851 and Vancouver) unexpectedly high risk of
CLE and LE significantly neutralized the LRC benefit.
However, it is hard to explain such low gain in two arms
of the RTOG 9003 (CB and HF) especially if compared
with the EORTC 22791 and MDACC trials.
Figure 4 generally implies that even if the doubts
concerning accuracy in the scoring and recording of con-
sequential and late effect would be accounted for there
still would be a room to increase dose intensity in order to
improve therapeutic gain.
19
Fig. 3. Locoregional control against Normalized Total Dose (NTD2.0)
without correction for overall treatment time.
[vertical lines represent decrease of the LRC to therapeutic gain due to
the incidence of late effects; solid lines represent the LRC – NTD, and
dotted line the TG – NTD relationships; area between two curves illustra-
tes the risk of costs-late effects. Graphic and letter symbols as in Fig. 1]
* Footnote: Assuming 60 Gy in 30 fractions is a standard regimen,
and the tested altered regimen (A) would be given in 1.6 Gy frac-
tions b.i.d. to a total dose of 62.4 Gy, one could say there is 2.4 Gy in-
crement in effective total dose (assuming overall treatment time is
the same in both regimens). However, it is not true, because there is
no increment in effective dose at all, and 62.4 Gy in regimen A is just
equivalent to standard 60 Gy (assuming α/β value of 15.0 Gy). If the
increase in effective dose would be 2.0 Gy, which is equivalent to 2.1
Gy in 1.6 Gy fractions, then total dose in regimen A should be 64.5
Gy giving therapeutic ratio of about 1.03 or 3% (64.5/62.4). On the
other hand, 10% gain in effective dose (ratio = 1.1) would give total
dose of 68.6 Gy and absolute increment in the effective normali-
zed dose (∆NTD) of 6.2 Gy (68.6 Gy – 62.4 Gy) instead of 8.6 Gy
(68.6 Gy-60 Gy). This example shows the way in which ∆NTD2.0 is
calculated, and should be interpreted.
I s  t u m o u r  r e p o p u l a t i o n  a m a j o r  d e t e r m i -
n a n t  o f  t h e r a p e u t i c  g a i n ?
Majority of altered regimens, including those analysed
in the present paper, were designed based on radiobiolo-
gical rationale that reduction in dose per fraction given
more often than one daily fraction produces sparing effect
in late responding normal tissues, and that shortening of
overall treatment time compensates accelerated tumour
repopulation. Fundamental guidelines have been rised
by Withers et al. [21, 5] suggesting that tumour clonogen
repopulation compensates on average 0.6 Gy/day after
a lag period of about 28 days (Fig. 4A – solid lines). De-
spite many uncertainties, the Withers' „dog leg” curve
was explored for at least the last 12 years as a basic ratio-
nale for altered accelerated and/or hyperfractionated stra-
tegies although the rationale came from the analysis of
a spectrum of predominantly retrospective studies. More-
over the length of the lag period can only be defined from
accurate estimates of TCD50 for advanced head and neck
cancers treated in short overall treatment time, however,
in fact they were not available at the time of analysis.
During the last decade many results of clinical trials
have been published, also those with the OTT of 28 days
and shorter. Total doses for altered regimens in the trials
reviewed in this paper are converted into NTD2.0 and re-
calculated as NTCD50 values, and they are plotted against
overall treatment time in Figure 4A. This figure shows
that at least ascending part of the original curve with the
slope of 0.6 Gy/day is far below the analyzed data points.
It suggest that the impact of accelerated repopulation on
treatment outcome might be higher than originally sugge-
sted by Withers et al. [5], and more than 0.6 Gy/day might
be compensated beyond day 28, and probably it is not
constant with the extension of overall treatment time. In
TROG 9101 and PMH trials, the NTCD50 values of 58.1
Gy and 56.4 Gy respectively for the OTT of 24 and 28
days suggest that between day 24 – 28 accelerated repopu-
lation is already ongoing. Assuming 0.6 Gy/day for that
short range of the OTT the lag period could be shortened
to 21 days. However, if it is true that well-differentiated
epithelial cancer respond better to altered regimens (as
observed in DH-7 and CHART) because they reflect the
characteristics of normal epithelium from which the tu-
mours have their origin, thus a lag period of even 14 days
sounds also reasonable.
In 1990 Cox et al. [22] published the results of the
RTOG 8313 trial testing efficacy of 4 different total doses
given b.i.d., and they observed no difference in therapeu-
tic gain for total doses in the range of 72.0 – 81.6 Gy.
The respective NTCD50 values are 69.8 Gy and 78.3 Gy.
Assuming 0.6 Gy/day to balance the repopulation, from
the difference in NTCD50 of 8.5 Gy, only 3.6 Gy (6 days
x 0.6 Gy/day) would be balanced by repopulation, and
the remaining 4.9 Gy should reflect an increase in the
therapeutic gain. However no gain was observed. It may
likely suggest that all 8.5 Gy could be balanced by accele-
rated repopulation, and consequently dose compensated
by repopulation per day would be 1.6 Gy instead 0.6
Gy/day, at least for the OTT of 6 weeks and longer.
A few recent trials, namely EORTC 22851, and
RTOG 9003 (arm HF, CB and S), convincingly suggest
that accelerated repopulation beyond day 28 of treat-
ment counterbalances about 1.1-1.2 Gy/day rather then
0.6 Gy/day. Thus, curve (a) and (b) on Figure 4B might
not be acceptable. The curve (c) gives the best fit to the
data, however the curve (d) reflecting the lag period of 21
days and an average rate of repopulation of 0.85 Gy/day
thereafter can not be neglected. It may suggest that higher
power for repopulation should be given if therapeutic
gain larger than 5-10% would be expected. For overall
treatment time longer than 4-5 weeks about 7 Gy/week
will be lost counterbalancing accelerated repopulation
instead of only 4.2 Gy/week. Therefore, only a part of
the increment in total dose, that above 7 Gy/week, may
have an effective impact on therapeutic gain.
The next and potentially interesting point to emerge
from Figure 4A is that NTCD50 of 68.7 Gy and 63.8 Gy
for the EORTC 22851 and CAIR trials differ only by the
fact that in the first trial a total dose was given in 5 days
and in the second one in 7 days per week. Therefore, by
extending irradiation on weekends instead of 5 days a we-
ek allows to decrease isoeffective dose by 4.9 Gy. If the
lag period of 28 days would be right, dose balancing tumo-
ur repopulation during weekends will be irrationally high
of 2.45 Gy/day, but if a lag period would be 21 days it
will give 1.2 Gy/day (4.9 Gy / 4 days – 2 weekends). The
latter one sounds radiobiologically more realistic. Inde-
pendently on assumption the estimates likely suggest that
repopulation during the weekends could be more effecti-
ve than during weekends.
I s  L RC  r a t e  f o r  c o n t r o l  i m p o r t a n t  f o r  o v e -
r a l l  t h e r a p e u t i c  g a i n ?
Recently Hliniak has pointed out (personal communica-
tion) that nobody knows why the control LRC level which
the LRC benefit is refered to is generally ignored. Let
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Fig. 4. LRC benefit (therapeutic gain) as a function of the increase
NTD2.0 (with correction for overall treatment time) for the tested alte-
red regimens as compared with control.
[solid line – LRC benefit; dotted line – therapeutic gain; area between
lines – CLE and LE costs; graphics and letter symbols as in Fig. 1; black
area within the graphics represents incidence of CLE; dose correction for
difference in the OTT between two arms was calculated using 0.6 Gy/day
and referred to the regimen with shorter OTT]
us assume the same LRC benefit of 15% for two different
trials. This may suggest that both trials are equally effec-
tive. However, it could not be true, since it would de-
pend to what level of the control LRC this 15% benefit
will be refered. If, for example, in one trial the control
LRC is 35% then altered regimen with the LRC of 50%
(15% benefit) will be 1.43 (43%) more beneficial than
the control. In contrast, the same increment in the LRC
but related to the control LRC of 55% will produce only
1.27 (27%) benefit.
According to that, the AH-S regimen in the RTOG
8809 is more beneficial (1.53) than HF regimen in
the EORTC 22791 (1.43) although the absolute LRC be-
nefits for this two regimens are quite in reverse (16% vs.
19%). Considering relative LRC rates, CHART and
DAHANCA-7 trials are almost equally beneficial (1.17
and 1.16) although the absolute LRC benefit for
DAHANCA-7 is higher than for CHART. The PMH
shows the LRC benefit similar to that for DAHANCA-7,
but relatively to the control level it is more (1.30) effecti-
ve than both DH-7 and CHART. These examples clearly
show how important is the efficacy of standard regimen,
to which altered regimen is compared.
If the control LRC is too low or too high, selection
bias is likely possible or the results might also be influen-
ced by the imbalance of known predictive and prognostic
factors.
The next important point is which part of dose-re-
sponse curve reflects the observed LRC benefit. If, for
example, the control LRC of 30% is on lower and ascen-
ding part of the curve, 10-15% increase in the LRC for
the tested arm needs probably higher increment in dose
(∆NTD2.0) than the same LRC benefit but reflecting ste-
eper upper part of the curve. To illustrate this problem the
LRC benefits representing only a part of the dose re-
sponse curve are plotted against relative increase in the
NTD2.0 (Fig. 5). An average dose-response curve estima-
ted for the segmental LRC curves is generally shallow
(Fig. 5 – dotted line) and it suggests that in the majority of
trials wide tumour and patient heterogeneity my bias the
results.
Finally, the costs (CLE, LE) accounted for may de-
crease the LRC benefit, even below the standard LRC, al-
though an overall therapeutic gain can still be observed as
it is in the case of Cairo, Vancouver and EORTC 22851
trials. Therefore, therapeutic gain although noted might
be misleading and in fact such trial should be conside-
red as negative.
I s  t h e r a p e u t i c  b e n e f i t  m o r e  e x p e n s i v e ?
There is general belief that sophisticated altered regi-
mens using more than one fraction per day or making
„weekend busy” should automatically be more expensive,
and they need higher total refund to cover an extra expen-
ses of unconventional treatment. It is also argued that
when shortening of overall treatment time by one or two
weeks gives some savings, maintenance and staff costs to
provide twice-a day treatment neutralize or even exceed
such savings. Dische calculated that the CHART expenses
are about 1000 pounds per patient higher than conventio-
nal irradiation [11]. The results of such calculation de-
pend on whether they are considered as hospital budget,
social or national costs or as a cost-effectiveness ratio.
The last way seems the most realistic.
Considering various medicare systems, and exchange
rates of currency in different countries, universal currency
units (u) were used for the present analysis. They can easi-
ly be converted into dollars, pounds or zlotys (multiplying
by the respective factor). Figure 6 illustrates the results of
costs-effectiveness analysis and shows that if the costs of al-
tered treatment are about 25% higher then standard total
refund of hospital expences should also increase. However,
when these costs are recalculated per one cured patient
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Fig. 5. NTCD50 values as a function of overall treatment time for advanced head and neck cancers estimated from the reports (letter symbols represent
authors and references), and normalized to 2.0 Gy fraction regimen. Constrains on data analysed were all H & N sites and stages included, LRC rate
in the range of 47%-82% (it minimalize extrapolation errors in estimating NTCD50), and α/β = 15.0 Gy. NTCD50 – time curve is originally estimated
by Withers et al. (24)
Original dose-time curve (a) estimated by Withers in 1988 with the average slope of 0.6 Gy/day after the lag period of 28 days compared with the curves
which give a better fit to the analysed data:
(b) constant slope of 0.6 Gy/day with the lag period of 21 days;
(c) biphasic slope of 0.6 Gy/day between day 21 and 38, and 1.2 Gy/day thereafter, and with the lag perior of 21 days;
(d) constant slope of an average 0.85 Gy/day after the lag period of 21 days and with the TCD50 of 53 Gy in the absence of accelerated repopulation (until
day 21)
the economic result of the expected therapeutic gain of
15% or 25% would decrease the expences at the national
level by at about 10-25% (4545-3845/5000). The calcula-
tion is focused on radiotherapy only, and in the case of
non-radical treatment extra costs of palliative radio-che-
motherapy, surgery of failures, and terminal care are not
accounted for the analysis.
At the level of hospital budget, if the total expenses
are reasonably lower than total revenue to keep hospital
on a good or at least safe economical condition, and the
fixed costs (maintenance) and changeable costs (employ-
ment and wadges) are well balanced (i.e. 3:5) thus the
hospital administration can easily calculate so called bre-
ak-even point (Fig. 7), that means, the number of pa-
tients needed to balance annual costs. More patients ad-
mitted above this number will make profit to the hospital.
If more expensive altered regimens are used (Fig. 7) then
the more patients are needed to reach break-even, and
overall financial profit will decrease. There is, of course,
the risk that total expenses would not be balanced by the
total refund leading to financial deficit. To keep hospital
budget on acceptable and safe level it needs decreasing of
fixed costs (about 5-8%), increasing the number of admit-
ted patients, or reducing employment (the last alternati-
ve is sometimes impossible to realize if the number of
employees is already restricted).
In summary, it seems important to know that the
expenses of a new altered regimens in radiotherapy do
not automatically lead to financial deficit of the hospi-
tal, and financial result strongly depends on the national
health care economics and on the hospital financial poli-
cy. On the other hand, however, if altered (or any highly
specialized) procedures are underpaid, there is a high
risk that its effectiveness would decrease substantially
(Fig. 9 – lower cube) or only a little but the risk of late ef-
fects (costs) will become unacceptably high due to treat-
ment inaccuracy caused by less technicians employed or
less money given to the procedure (Fig. 9 – upper – right
cube). That means that the patient will be either uncured
but without late complications or cured, however serious
late effects may heavily threaten his quality of life. In
both situations the result is not that which one would
expect to achieve. This consequences have to be keep in
mind by decision making administrators when they plan
the costs of a single procedure and whole budget for the
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Fig. 6. LRC benefits plotted as a segment dose-response curves against
relative increase in the NTD2.0 (∆NTD2.0) [dotted line is an average es-
timated dose-response curve]
Fig. 7. Costs – effectiveness analysis of expenses of the standard and altered radiotherapy. Lower curves illustrate
change in costs for altered vs. standard RT. Upper curves illustrate the costs calculated per one cured patients [u –
represent universal currency unit which can easily be converted into individual national occurency]
hospital. In the field of oncology, finances similarly to
tumour biology and treatment strategies, follow the rules
of „all or none” phenomenon.
Fu t u r e  p e r s p e c t i v e s  a n d  l i m i t a t i o n s
Present review of the 12 trials on altered radiotherapy
for head and neck cancer leads to many uncertainties
and doubts. Obviously the aim of all trials is to find an
average „golden” key to treat various tumour stages and
site, although in the majority of studies they have been
groupped together. It appears there is not a single, an-
swer, and perhaps different sites, stages and tumour diffe-
rentiation needs different fractionation schedules.
Overall LRC benefit in favour of altered regimens is
generally in the range of 5- 9 % with a wide variation in
the increase in effective NTD2.0, sometimes being not
adequate to the LRC achieved. It is also possible the on-
set and quantity of accelerated tumour clonogen repo-
pulation of 0.6 Gy/day is likely underestimated. The dose
counterbalanced by repopulation could be at least 0.85
Gy, or even higher (1.1-1.2 Gy/day) during the weekends,
and lag period might be shorter than 28 days, and 21 days
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Fig. 8. Break – even analysis for overall hospital budget if altered fractionation regimens (dotted lines) is used in-
stead of standard radiotherapy (solid lines). Break – even point represents the number of patients required to ba-
lance all expenses. The use of altered treatment with 25% higher costs needs extra 120-220 patients to balance the
hospital expenses.
Fig. 9. „Two times two” decision – making square. Optimum benefit (the highest LRC with the lowest risk of late ef-
fects) can be expected for the most effective fractionation regimen and full refund of the hospital expences. The use
of optimal treatment but with only partial refunding shifts the treatment to much less effective and/or higher risk of
late complications.
or even 14 days sound realistic. Consequently, the size
of effective dose increment might be lower than reported.
Being back from the ranch of these 12-15 years of
extensive studies to daily practice, only two or three alte-
red regimens (DH-7, CAIR, concomitant boost) became
a standard treatment. During these years we learned that
time dilution is likely a significant enemy of dose intensi-
ty and the size of LRC benefit since only 0.71 of overall
treatment time is effectively used in continuos irradia-
tion during in 5 days a week, whereas it is clearly docu-
mented that any breaks during radiotherapy, therefore
weekends also, are detrimental for treatment outcome.
Furthermore, the LRC benefit can be lower than reported
due to unprecise scoring and recording of late effects.
But even if not, an overall therapeutic gain is moderate in
the range of 0-15% (Fig. 8).
Despite many doubts and uncertainties, altered frac-
tionation regimens still remain promising perspective.
Because improvement in therapeutic gain may likely be
seriously constrained by the intention to use total doses
limited to the level of acute tolerance, there still should
be a room for further dose escalation, with the reduction
of treatment time. Kaanders et al. [3] suggest that doses
around 60 Gy in 3-4 weeks are probably within the li-
mits of tolerance (Fig. 8). The TROG 9101 trial with
AHF schedule of 59.4 Gy given b.i.d. in 24 days produ-
cing the LRC rate of 54% for advanced head and neck
cancers clearly supports this idea. It may be advantageous
to escalate the dose towards the end of treatment when
the mucosa is most actively repopulating [7, 8]. In order
to spare late responding tissues the size of dose per frac-
tion should be of less than 1.8 Gy, and then given b.i.d.
with interfraction interval of at least of 6 hours (even
about 12 hours for spinal cord). However, the use such
schedule only 2- or 3 days-a-week generally produces
negative therapeutic gain [23]. Even 5 days a week irra-
diation does not seen effective enough, and very intensi-
ve treatments can only be delivered escalating the dose
beyond working days, that means, including weekends. In
such case, time intensity would increase to 1.0 and may
effectively enhance the effect of dose intensity to increase
therapeutic gain. In this field, the DH-7 and CAIR re-
sults give intriguing perspective. Chemo- or brachythera-
py acceleration at the end of treatment may also be con-
sidered.
It has to be remembered, however, that for such in-
tensive treatments safe window is narrow, and small diffe-
rences in time or dose of only few days or a few Gray
can shift enhanced but still acceptable mucosal morbidity
towards very severe and consequential intolerable late
complications which may off-set sparing effect of altered
fractionation [24]. When, the limit of acute tolerance is re-
ached application of any potent agent which can prevent
or diminish acute mucositis is of practical value. Unfortu-
nately, drugs with sufficient potency have yet to be iden-
tified. Therefore, supportive care with corticosteroids,
antibiotics, antiinflammatory drugs and parental nutri-
tion, ordered early, may effectively diminish severity of
acute effects.
There are about two decades of extensive randomi-
zed studies involving thousands of patients and produ-
cing interesting perspectives, but the question what should
be the best modified fractionation regimen for specific
tumour site and stage still remains widely open. Undoub-
tedly, individual patients and tumour characteristics need
individual tailoring of the treatment regimen, and proba-
bly there are many keys, and therefore, there is a need of
highly specific molecular and cellular predictors to find
proper keys to proper doors.
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Fig. 10. Scheme of status of art of the benefit in favour of altered fractionation schedules and the proposed per-
spectives.
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